Introduction
Genes responsible for leukemic transformation are frequently located near non-random chromosomal translocations (Rabbitts, 1994; Rowley, 1999) . However, in approximately 50% of the clinically diagnosed myeloid leukemias no cytogenetic abnormalities have been detected. Furthermore, in a number of cases that do carry a cytogenetic abnormality (Cox et al., 2001; Specchia et al., 2001; Tanaka et al., 2001 ) the genes located near the breakpoints are still unknown. Moreover, since leukemia is believed to be a multi-step process, aberrant expression of different disease genes affecting multiple pathways are required to obtain full leukemic transformation (Berns et al., 1994 (Berns et al., , 1999 ). An alternative procedure to identify leukemia disease genes is the cloning of common virus integration sites (cVIS). This approach has proven to be a sensitive tool to identify novel proto-oncogenes as well as tumorsuppressor genes. In fact, several genes located near chromosomal breakpoints or otherwise aberrantly expressed in human hematopoietic malignancies have been identified through retroviral insertional mutagenesis in murine leukemias or lymphomas as well, e.g. Evi1 (Morishita et al., 1988 (Morishita et al., , 1990 , Evi2 (NF1) (Buchberg et al., 1990; Shannon et al., 1994; Side et al., 1998) , Evi6 (Hoxa9) (Nakamura et al., 1996a,b) , Bcl1 (Cyclin D1) (de Boer et al., 1997; Silver and Buckler, 1986) , N-Myc (Hirvonen et al., 1993; Setoguchi et al., 1989) , and Erg (Shimizu et al., 1993; Valk et al., 1997c) . A major assumption in studies of MuLV-induced leukemias is that proviral integration is essentially random and that common sites of integration are observed in tumor samples due to selection of rare cells with proviral insertions in these common sites. The selective pressure is provided by the expression of the target gene nearby (Berns et al., 1994 (Berns et al., , 1999 . Although one might suspect that common as well as non-common VISs will be present in a leukemia, it is at present unclear which percentage of VISs in a particular tumor represents common sites of integration. In this study, we developed a highthroughput procedure to clone novel cVISs on a large scale to answer this particular question.
Until recently, the identification of cVISs has been a laborious procedure. In order to isolate cVISs and potential disease genes on a large scale, PCR approaches were previously established, e.g. an inverse PCR (IPCR) and a RT -PCR based procedure (Valk et al., 1997c; Silver and Keerikatte, 1989) . Making use of IPCR and subsequent automated DNA sequencing investigators identified VISs on a large scale using AKXD-or BXH2-virus-induced leukemias (Hansen et al., 2000; Li et al., 1999) . By comparison of every virus flanking fragment with sequences in the GenBank of the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov, NCBI, Bethesda, MD, USA) and with the nucleotide sequences of each of the other cloned virus insertions, a significant number of novel common integration sites and potential disease genes were identified. On the other hand, a large number of virus insertions were found only once. Although these insertions had frequently taken place in key regulatory genes, commonality could not be shown using this approach. Here we present a strategy in addition to the PCR/high-throughput sequencing protocol, to not only identify large numbers of virus integration sites, but also rapidly define whether a virus insertion represents a cVIS.
Swiss mice infected with Cas-Br-M MuLV may develop myeloid or lymphoid malignancies as the result of retroviral insertion in disease genes (Bergeron et al., 1991; Holmes et al., 1986) . Classical cloning procedures resulted in the identification of several disease genes in Cas-Br-M MuLV-derived tumors, e.g. Evi1, Evi11/Cb2 or Evi12 (Morishita et al., 1988; Valk et al., 1997b Valk et al., , 1999 . Large scale IPCR and RT -PCR was performed utilizing DNA or mRNA from 28 primary Cas-Br-M MuLV-induced myeloid leukemias in Swiss mice (CSL) (Joosten et al., 2000) and 15 retrovirally induced myeloid cell lines (Holmes et al., 1985; Ihle et al., 1984) . Virus-flanking fragments were cloned, sequenced and subsequently compared to the Celera Discovery System (Contents of May 2002) (www.celera.com, Celera Genomics, Rockville, MD, USA) and to NCBI Genbank. To investigate whether these sites represented cVISs, we developed a nested PCR strategy on genomic DNA from 107 leukemias, by applying LTRspecific and fragment-specific primers followed by a Southern blotting protocol with an additional set of ratio-labeled LTR-and fragment-specific oligonucleotides. Applying this approach, we were capable of defining whether and how frequent a virus insertion occurred in other leukemias. In addition to six previously identified cVISs we identified a large number of novel common virus insertions. The exact mouse and human chromosomal localization were defined and in most of the cases the potential target genes in these loci could be identified.
Results
To clone VISs on a large scale, a virus-LTR specific IPCR as well as a RT -PCR were applied as complementary approaches using DNA or RNA from 43 myeloid leukemias. The IPCR method was carried out on 28 primary leukemias and nine cell lines, whereas the RT -PCR based technique was performed on 12 cell lines and two primary leukemias. The fragments were cloned, subjected to nucleotide sequencing and compared to each other and to those present in the Celera and NCBI databases. In total 126 unique virus integration sites were identified of which some were found more than once in distinct leukemias. Database analyses revealed three different groups of virus integrations: i.e. (I) in a gene (65/126), (II) in a known genomic locus in the vicinity of a gene (57/126), and (III) in an unknown sequence (4/126) ( Table 1) .
We next determined for 41 inserted loci whether they represented a cVIS. This concerned 20 integrations from Group I and 21 sequences from Group II (Table  1) . We designed locus specific primers for each of the virus insertions and carried out a nested PCR reaction using these primers in combination with LTR specific primers on genomic DNA isolated from 107 tumors, i.e. 87 primary CSLs, 11 DA cell lines and nine NFS cell lines (see Figure 1) . The PCR products were run on an ethidium bromide stained 1.5% agarose gel, subjected to Southern blot analysis and hybridized with locus specific primer-C and pLTR3 (Figure 1 ). Fragments that hybridized to both primers were considered positive. In each experiment, two or more of those positive fragments were cloned and sequenced to confirm specificity and to acquire more nucleotide sequence information of the loci (Figure 1) .
The PCR/Southern strategy was applied on 20 of the 65 integrations from Group I (insertion in a gene). It appeared that 19 of the 20 integrations analysed represented a common VIS. These 19 loci, including their frequency, the tumors from which the virus integrations were originally isolated, the murine and human chromosomal localization, the NCBI accession numbers of the viral integrations, the Celera protein accession numbers, and the (putative) function of the gene products are summarized in Table 2 . Using the PCR/Southern strategy we identified several previously cloned cVISs, i.e. Evi1, Hoxa7, c-Myb, Evi11/Cb2, Evi12 and His1. For the other 13 cVISs, i.e. Casvis 1 -13 a known or a novel putative gene was identified. Three of them, Casvis 1, 2, and 3, were located in genes encoding nuclear proteins, i.e. Transcription elongation factor II, Dnmt2, and Nm23-M2 respectively. We found integrations in two genes encoding membrane receptors, i.e. Cb2 and mrc1. Recurrent viral integrations were also found in the gene encoding the enzyme Hmox2, a tyrosine kinase. Furthermore, genes encoding the carrier proteins Slc7a11 and Slc17a5, being sodium-dependent phosphate transporter-related proteins and the ringfinger protein Midline-1 were very often inserted by retroviral DNA. Finally a number of genes encoding novel putative proteins were identified as frequent common virus integration sites (Casvis 11 -13 and Evi12).
In Table 3 common insertion sites are listed in which virus DNA had integrated into a genomic sequence at a relative distance from a potential target gene (Group II). Using the PCR/Southern procedure, 19 out of 20 integrations from Group II were identified as cVIS (Casvis 14 -33). Recurrent viral insertions were found in loci encompassing genes that encode for the transcriptional regulators Erg and LIM domain binding protein 1, the signaling molecule PKCe, the TGFb receptor and the Rap guanine nucleotide Novel disease genes in mouse leukemia M Joosten et al exchange factor. In 11 cases the candidate genes encode unknown putative proteins. Our data demonstrate that the majority of virus insertion sites analysed by PCR/Southern represent common VISs, suggesting that the majority of the remaining integrations should be considered as disease loci as well. Therefore, the remaining 45 integrations from Group I (insertions in a gene) and 36 insertions from Group II (insertion in the vicinity of a potential target gene) are summarized in Tables 4 and 5 respectively. Of these remaining virus integrations, eight were found more than once within the distinct leukemias and were therefore designated Casvis 34 -41 (Tables 5 and 6 ).
Discussion
The identification of cVISs has previously become less labor-intensive through the development of various PCR procedures. In the present study we used two distinct complementary PCR procedures and applied an additional PCR/Southern strategy ( Figure 1 ) to further increase the speed of identifying novel cVISs. Using these techniques we identified 126 virus integration sites in Cas-Br-M MuLV-induced myeloid leukemias and determined that 39 of 41 insertions analysed represented a common VIS. Based on these findings, it may be deduced that of the other virus integration sites a comparable high percentage may in fact represent cVISs as well. PCR/Southern blotting analysis in the panel of leukemias using locus-and LTR-specific primers should assure whether this is indeed the case. The detection of previously cloned cVISs and their corresponding leukemia genes (Evi1, Hoxa7, c-Myb, Cb2/Evi11, His1 and Evi12) indicates that the PCR/Southern based technique that we applied is reliable. It also emphasizes the significance of the novel cVISs found, and warrants further exploration of the strategy to clone the large number of cVISs and disease genes that remain to be identified in leukemia and lymphoma.
The frequency of proviral insertions is sometimes exceptionally high, e.g. 58% for Hoxa7 and Transcription elongation factor SII or 55% for Midline-1. Many other insertions were found at frequencies between 10 and 30%. In fact only a minority of common integrations were found at a frequency lower than 10%. The most likely explanation for these high frequencies is that these retrovirally-induced leukemias are oligoclonal (Li et al., 1999; Ofir et al., 1992) . In fact, proviral insertion in certain genes (e.g. Nm23-M2 or Mid-1) identified by the PCR/Southern strategy, were undetectable by applying classical Southern blotting (data not shown), suggesting amplification of proviral integrations present in a minor clone. Since leukemia development is believed to be a multigenetic process it will be important to dissect which disease genes frequently cooperate in transformation. A thorough analysis of the large series of common integrations found in this cohort of leukemias should reveal which disease loci frequently coincide. However, oligoclonality does not allow a reliable analysis to identify cooperation between disease genes in these virus-induced tumors, a caveat also being recognized by other investigators (Li et al., 1999; Ofir et al., 1992) . Serial transplantations or in vitro immortalization of these tumors may be applied to separate clones to study the combinations of genes required for full transformation.
One group of genes frequently targeted by retrovirus comprises the ones that encode for nuclear proteins involved in transcriptional control or other nuclear functions. The fact that this group of genes is so often subject to mutations in mouse leukemias as well as in human disease underlines the critical role these proteins may have in development and indicates that mutations in those genes are key events in leukemic transformation. Among integrations in previously reported DNAbinding protein genes Evi1, Hoxa7 and c-Myb, we also found frequent proviral insertions in a region in the vicinity of Erg. The latter gene is the murine homologue of human ERG, which has been shown to be expressed as TLS/ERG fusion gene in human AML with translocation t(16;21)(p11;q22) (Shimizu et al., 1993) .
The high-throughput search for novel cVIS provides a unique opportunity not only to clone novel transforming genes but may also lead to the identification of new disease pathways that have not previously been implicated in leukemia. Several novel potential disease genes have been identified as frequent proviral targets in our screen, which may relate with novel pathways. Among these are the Mid-1 gene encoding g Number of virus integrations that were found more than once among the remaining 85 virus insertion sites and designated cVIS as well Novel disease genes in mouse leukemia M Joosten et al the Midline-1 ringfinger protein, which is mutated in patients with Opitz-syndrome (Quaderi et al., 1997) and Nm23-M2 a gene of which a human homologue has been identified as a critical gene in lymphoma development. A large set of common virus insertion sites were identified harboring novel genes, encoding for putative proteins, with unknown function. Each of these novel disease loci may become of interest following further cloning, characterization and functional screening using in vitro and in vivo models.
Obviously, the PCR based strategies used are highly sensitive and almost every insertion that was found represented a common VIS. It is possible that certain VISs, particularly the ones found less frequently (55%), have been pulled out due to the high sensitivity of our approach, and may not resemble Figure 1 IPCR or RT -PCR was performed on RNA or DNA from cell lines (DA and NFS), or CSL leukemias. The resulting virus flanking fragments were subjected to sequence analysis. LTR-and locus-specific primers were designed and used in a nested PCR strategy (*), i.e. LTR-1/primer-A PCR, followed by a LTR-2/primer-B amplification using genomic DNA from a panel of CasBr-M MuLV-induced leukemias. PCR products were electrophoresed on a 1.5% agarose gel and subsequently blotted. Blots were first hybridized with locus-specific primer C and exposed to film, and after stripping rehybridized with primer LTR3. Bands hybridizing with the LTR3 as well as the locus specific primer C (lanes 1, 2, 3, 6 and 8) were considered positive, i.e. tumors carrying this particular cVIS. Hybridization with one primer only (lanes 4 and 7) are false positives. In each experiment two or three positive fragments were cloned and nucleotide sequenced to confirm specificity Novel disease genes in mouse leukemia M Joosten et al Accession numbers from Celera discovery system were from May 2002. It should be noted that the mouse assembly of Celera discovery system is dynamic and will be improved over time. The frequency of Evi1, Evi11 and Evil2 was determined by Southern blotting instead of the PCR/Southern procedure (Valk et al., 1997c (Valk et al., , 1999 Proviral integrations occurring within a certain distance of a gene. Distances between proviral insertions and potential target genes are presented in the last column. For further explanation, see Table 2 Novel disease genes in mouse leukemia M Joosten et al disease loci. However, additional approaches are required anyway to further select for the critical genes that play a major role in leukemic transformation. An important question to be answered in the near future, is whether the genes identified in our in vivo functional screens are of importance for the development of human disease. As a final filter, high-throughput nucleotide sequencing, real-time PCR and gene-array analysis should prove the role of these genes in the development of human AML.
Materials and methods

Primary leukemias and cell lines
The NIH-Swiss derived Cas-Br-M MuLV-induced primary tumors used in this study are: for IPCR: CSL 13, 16, 20, 22, 26, 30, 31, 32, 33, 65, 71, 78, 82, 90, 91, 93, 111, 117, 123, 201, 203, 204, 212, 221, 227, 228, 237 and 239; and for RT -PCR: CSL: 201 and 203 (Joosten et al., 2000) . Cells isolated from leukemic spleens were stored vitally in aliquots in liquid nitrogen. The following leukemia cell lines were utilized in Proviral integration occuring within certain genes. a Integrations in Casvis 34 -37 were found in more than one distinct leukemia. The number of independent leukemias in which these integrations were detected is between brackets in the first column. No virus insertion name was given yet for insertions found only once. For further explanation, see Table 2 this study: for IPCR: DA 24, and NFS 22, 36, 56, 58, 60, 61, 78, and 124; and for RT -PCR: DA 1, 2, 3, 8, 33, and NFS 22, 36, 58, 61, 78, 107 and 124 (Valk et al., 1997a) . These cell lines were cultured in RPMI plus 10% fetal calves' serum (FCS) (Gibco Life Technologies Inc., Gent, Belgium) and 10 Units of mouse IL3. The frequency of virus integrations was determined both on cell lines (DA 1, 2, 3, 8, 13, 24, 25, 28, 29, 31, 33, and NFS 22, 36, 56, 58, 60, 61, 78, 107 and 124) , and primary leukemias (CSL 11, 12, 13, 14, 15, 16, 17, 19, 21, 22, 23, 25, 26, 27, 29, 31, 32, 33, 35, 36, 38, 39, 41, 43, 45, 46, 47, 48, 49, 50, 51, 53, 54, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 85, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 114, 117 and 123) .
IPCR and RT -PCR
Isolation of genomic DNA was carried out exactly as described previously (Valk et al., 1999) . Five mg of genomic DNA was digested with Sau3A, PvuII or SstI (GIBCO Life Technologies Inc., Gent, Belgium). The products were treated with T4-ligase (GIBCO Life Technologies Inc.), which resulted in the formation of circularized products. Subsequently we performed an IPCR strategy using primers specific for the Cas-Br-M MuLV LTR. For the Sau3A digested/ligated fragments, the first PCR reaction was carried out with primers pLTR4 (5'-CCG AAA CTG CTT ACC ACA-3') and pLTR3 (5'-GGT CTC CTC AGA GTG ATT-3'), followed by a nested PCR using pLTR5 (5'-ACC ACA GAT ATC CTG TTT-3') and pLTR6 (5'-GTG ATT GAC TAC CCG CTT-3'). Cycle conditions for both PCRs were 15 s at 948C, 30 s at 578C, and 2 min at 728C for 10 cycles, and an additional 20 cycles following the conditions 15 s at 948C, 30 s at 578C, and 2 min 30 s at 728C. Reactions were performed using Expand High Fidelity PCR System (Roche, Mannheim, Germany). For PvuII and SstI digested genomic DNA, the circularized DNA was amplified using primers pLTR7 (5'-GAC TCA GTC TAT CGG AGG AC-3') and pLTR1 (5'-CTT GCT GTT GCA TCC GAC TGG-3'), and pLTR8 (5'-GTG AGG GGT TGT GTG CTC-3') and pLTR 2 (5'-GTC TCG CTG TTC CTT GGG AGG-3') respectively. Integrations in Casvis 38 -41 were found in more than one distinct leukemia. The number of independent leukemias in which the integrations were detected is between brackets in the first column. For further explanation, see Table 2 The first PCR was performed for 30 cycles 30 s at 948C, 1 min at 548C, and 3 min at 728C. Reactions were carried out with Expand High Fidelity PCR system (Roche). Nested PCR conditions were 30 cycles of 30 s at 948C, 1 min at 588C, and 1 min at 728C. This reaction was performed with Taq polymerase (Amersham Pharmacia Biotech, Roosendaal, The Netherlands). RT -PCR was carried out as described previously by Valk et al. (1997c) . Briefly, total RNA was isolated through a CsCl gradient. First strand cDNA was obtained by reverse transcriptase (RT) reactions with an oligo(dT)-adapter primer (5'-GTC GCG AAT TCG TCG ACG CG(dT) 15 -3') at 378C with 5 mg RNA, using the Superscript TM Preamplification System (Life Technologies, Breda, The Netherlands) according to the instructions of the manufacturer. Subsequently, PCRs (1 min at 948C, 1 min at 588C, 3 min at 728C (30 cycles)) were performed on the RT reactions of the leukemias by using the LTR specific primer pLTR6 and the adapter primer (5'-GTC GCG AAT TCG TCG ACG CG-3'). PCR products were directly cloned into pCR2.1 (Invitrogen, Breda, The Netherlands) according to the instructions of the manufacturer and subjected to nucleotide sequencing. Nucleotide sequences were compared to the NCBI database for analysis.
PCR analysis and Southern blot hybridization
One mg of genomic DNA isolated from primary leukemias or cell lines was subjected to PCR with primer pLTR1 and a locus specific primer A (Figure 1 ). Locus specific primers of 17 -21 nucleotides were designed specific for each of the sequences of the fragments generated by Inverse-or RT -PCR. Primers were purchased from Life Technologies. One ml of PCR product was transferred to a nested PCR reaction using primer pLTR2 and a nested locus specific primer B. Cycle conditions for both reactions were 1 cycle 5 min at 948C, 30 cycles 30 s at 948C, 1 min Tm, 1 min 30 s at 728C, 1 cycle 5 min at 728C. Tm was specific for each primer and was between 488C and 628C. PCR was carried out using Taq polymerase (Amersham Pharmacia Biotech). PCR products were electrophoresed in a 1.5% agarose gel and transferred to Hybond-N + nylon membranes (Amersham Pharmacia Biotech) with 0.25 M NaOH/1.5 M NaCl. Membranes were hybridized with a 32 P-end-labeled locus specific primer C. Labeling was carried out using T 4 kinase (USB, Cleveland, OH, USA) according to the instructions of the provider. Subsequently, blots were stripped in 0.4 M NaOH for 30 min at 458C, neutralized using 0.2 M Tris-HCl, 0.2% SDS, and 0.16SSC for 15 min at 458C and hybridized with 32 P-endlabeled Cas-Br-M MuLV specific primer pLTR3. Blots were exposed for autoradiography with a KODAK film and an intensifying screen. After 15 min of exposure films were developed and analysed.
Sequencing analysis
Samples were prepared using the Bd-sequencing kit according to instructions from the provider (PE Biosystems, Nieuwerkerk a/d IJssel, The Netherlands) and nucleotide sequencing was carried out on an ABI 310 automatic sequencer (PE Biosystems) using primers M13forward (5'-GTA AAA CGA CGG CCA GT-3') and M13reverse (5'-GGA AAC AGC TAT GAC CAT G-3'). Sequences isolated by IPCR or RT -PCR were compared to the data present in the Celera Discovery System (Celera Genomics, Rockville, MD, USA, database contents May 2002) and in the GenBank of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA). The exact site of integration was determined. For insertions found outside a gene, the distance between the integration and the most nearby gene was calculated. The location on the mouse chromosome was established and the human equivalent was deduced by using the human databases of Celera Discovery System (May 2002), LocusLink or human mouse homology maps (both www.ncbi.nlm.nih.gov).
